Background: Despite remarkable advances in our understanding of asthma, there are
Despite remarkable advances in our understanding of this condition, and the availability and current development of novel medications for the treatment of asthma, many asthma patients remain uncontrolled, which imposes a significant ongoing burden.
Uncontrolled pediatric asthma is associated with increased exacerbation rate, impaired quality of life, and persisting bronchial obstruction. 8, 9 Current clinical practice guidelines do not always adequately address pediatric asthma, a feature that is probably linked to the limited availability of clinical efficacy and safety data in younger patients, often resulting in an extrapolation of adult recommendations to children. This dearth of evidence may impact on local reimbursement or resourcing policies and therefore on the accessibility of potentially effective medicines for this patient population.
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There is an urgent need for an up-to-date assessment of the true burden and unmet needs of asthma patients, and their families, to ensure appropriate support to meet these needs. Provisions to ensure better asthma control at an earlier stage may facilitate improved quality of life and significant long-term cost savings for both asthma sufferers and society. 11 This article is a scoping review of the current unmet needs of children with asthma (Table 1 ) and the potential role for effective therapies in this vulnerable patient population. Content has been developed from review of the literature and synthesized with expert opinion during a face-to-face, two-day meeting with a group of international expert clinicians and scientists in pediatric asthma management.
| UNME T NEEDS IN PED IATRI C A S THMA

| Guidelines that acknowledge the management of different asthma phenotypes
Diagnosing asthma and establishing control as early as possible in childhood are considerable clinical challenges. Clinical practice guidelines are in place to support healthcare practitioners (HCPs) in the management of pediatric asthma 12, 13 ; however, these may not be totally suitable to ensure optimal management of asthma in the reallife, day-to-day clinical setting. This is largely due to a lack of relevant evidence and different patterns of asthma in children. 13 of age. An increased focus on children is needed in the context of clinical practice guidelines for asthma; current pediatric practice relies mostly on extrapolations from adult recommendations. Furthermore, no uniform definition of pediatric asthma exists, which hampers timely and robust diagnosis of the condition in affected patients.
Conclusions:
There is a need for a uniform definition of pediatric asthma, clearly distinguishable from adult asthma. Furthermore, guidelines which provide specific treatment recommendations for the management of pediatric asthma are also needed. Clinical trials and real-world evidence studies assessing anti-immunoglobulin E (IgE) therapies and other monoclonal antibodies in children <6 years of age with asthma may provide further information regarding the most appropriate treatment options in these vulnerable patients. Early intervention with anti-IgE and non-steroid-based alternative therapies may delay disease progression, leading to improved clinical outcomes.
K E Y W O R D S
asthma management, omalizumab, pediatric asthma, unmet need The inability to reach a robust and universal definition of asthma is not a new phenomenon and is evidenced by the differing approaches currently in existence. These discrepancies have been extensively discussed by the International Consensus on (ICON) Pediatric Asthma group, where they also highlighted a lack of distinction in any current asthma guideline between the definitions of adult versus pediatric asthma. 13 Of note, the Lancet Asthma Commission has recently put forward a new proposal to use "asthma" to describe a collection of overlapping symptoms, rather than as a single disease entity or an indicator for a specific pathophysiology. 25 Interestingly, this approach is similar to the original use of the word "asthma" by Homer more than 2500 years ago. Table 2 describes a number of potential roles of the specialized care center for pediatric asthma. Although patient referral recommendations are addressed in clinical practice guidelines, failure to promptly refer a patient from primary to specialist care is a potential barrier to the effective management of pediatric asthma.
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In countries where a significant portion of asthma management is delivered in busy primary care clinics, GPs/PCPs are in an important position to identify uncontrolled or difficult-to-treat asthma.
The importance of local factors in the primary care setting should not be overlooked; local environmental triggers of symptoms and the ability to adapt global strategy documents to suit local needs should also be considered. 27 An extensive overview of guideline recommendations for the referral of adults with asthma is available.
14 Similar guideline-defined recommendations are relatively limited for children, although the Canadian pediatric guidelines do recommend referral in the case of diagnostic uncertainty or uncontrolled asthma on medium-dose ICS. 28 It is critical that local healthcare systems have clear guidance in place to support GPs/PCPs in the referral of such patients to a specialist in appropriate instances, but this is not always available. This guidance is important as it is not feasible to expect a GP/PCP to have the time or resources to optimize treatment in difficult cases, owing to the very broad range of conditions and patients presenting to primary care facilities. 29 The use of electronic diaries and mobile health technology may significantly improve the management of pediatric asthma, and the communication between the GP/PCP and the specialist. 30, 31 Increased awareness of effective referral strategies and improved communication between GPs/PCPs and specialists may improve the rate of appropriate referrals. 29 The time to referral will ultimately depend on local healthcare regulations and resources of GPs/PCPs. 
| Effective treatment options
As with adults, the ultimate goals of pediatric asthma management include adequate symptom control and reduced future risks. 12 Natural history modification and possible disease prevention are also of high importance in children. 33 Achieving asthma control usually requires pharmacological intervention, including controller medication, rescue medication, and add-on therapy, in the case of severe asthma.
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Equally as important are the non-pharmacological treatment approaches, which are frequently underestimated. These include patient education and trigger avoidance (eg, minimizing exposure to pollutants and allergens to reduce asthma-associated morbidity). 34, 35 Corticosteroids play a central role in the pharmacological management of asthma. Over the last six decades, the clinical effectiveness of corticosteroid treatment in asthma has been demonstrated. [36] [37] [38] The mainstay controller medication used in pediatric asthma to limit airway inflammation is an ICS, as it has been shown to significantly improve lung function 39 and reduce exacerbations.
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However, ICS dose regimens that are suitable for the pediatric population vary across different guidelines, as do the thresholds used to define low-, medium-, and high-dose ICS. There is also high variability of dose delivered according to device choice. 41 The need for guidelines to be updated according to ICS dose responses has also been highlighted previously. or growth retardation in children. [44] [45] [46] [47] As the incidence of adverse events is often dose-dependent, the minimum effective dose in order to achieve uncompromised asthma control should always be considered. Similar efficacy data are still unavailable for patients <6 years due to a lack of appropriate studies.
| P OTENTIAL FOR B I OLOG I C S A S NON -S TEROID -BA S ED TRE ATMENTS IN PEDIATRIC A S THMA
An important question in the era of stratified medicine is what can be done beyond corticosteroids. Stratified or personalized medicine recognizes that the underlying mechanisms of asthma can vary significantly between patients, and it is widely acknowledged that there is a need for non-steroid-based treatment approaches in the management of asthma, especially in children. patients is based largely on clinical judgment, expert opinion, and cost of medications owing to the lack of clinical evidence in this particular patient population. 54 As described previously by Szefler and colleagues, "the younger the child, the less information there is available to guide clinicians". 33 We would also add that the younger the child, the later he/she can benefit from medical progress.
Omalizumab is currently the only anti-IgE monoclonal antibody with an approved indication in children ≥6 years (EU). In the EU, omalizumab is approved as add-on treatment in patients ≥6 years of age with severe persistent allergic asthma that is not sufficiently controlled with ICS plus LABA therapy 55 and in the United States (US) for patients ≥6 years with moderate-to-severe persistent asthma with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms that are not sufficiently controlled with ICS monotherapy. 56 This labeling excludes asthma patients <6 years who might benefit from anti-IgE therapy and limits the add-on therapy options available to physicians. Studies demonstrating the efficacy and safety of omalizumab in pre-school children and milder patients are currently in planning, while similar studies involving other biologics are urgently required. Mepolizumab is an anti-IL-5 monoclonal antibody approved for the treatment of patients ≥18 years (≥12 years in some countries) with eosinophilic asthma, and it is encouraging to note that other anti-IL-5Rα and anti-IL-4Rα therapies are currently under investigation in patients ≥12 years. 53 Although the results of studies of these biologics, including mepolizumab 57,58 and benralizumab, 59 ,60 are a very positive step forward for patients with asthma, it is disappointing that only a limited number of adolescents were included in these initial trials. 61 Furthermore, the efficacy of these promising therapies in patients below this age threshold (<12 years) is entirely unknown. It would be unfortunate if today's pediatric patients reach adulthood without getting the opportunity to experience the potential benefits that any of these biologic therapies may have had on their asthma and quality of life. For this reason, more studies of longer duration that include children of all age groups are urgently needed to provide additional data on the efficacy of these biologics. However, the authors acknowledge that the relatively low prevalence of severe refractory asthma in younger children may impede the recruitment of these patients for such studies. 
| UNANSWERED QUE S TIONS FOR OMALIZUMAB THER APY IN THE PED IATRIC A S THMA P OPUL ATI ON
Considerations for omalizumab therapy in pediatric patients are listed in Table 3 . Viruses, particularly rhinoviruses, are associated with the majority of asthma exacerbations in children, which occur frequently during the autumnal season upon the recommencement of the school year. The results of the PARK and EXPECT 69 (discussed later) studies may add further insights.
Pediatric asthma patients often suffer significant multi-morbidity, including allergic rhinitis and food allergy. 70, 71 Importantly, omalizumab has been shown to be effective in allergic rhinitis (by significantly improving total Rhinitis Quality of Life Questionnaire score). 72 Furthermore, the efficacy of omalizumab in patients with food allergy is encouraging; omalizumab decreased or eliminated food allergy symptoms upon accidental exposure to foods against which they were sensitized. 73 However, there is still a paucity of evidence for similar therapeutic action in affected patients <6 years of age. This suggests an unmet need to investigate the efficacy of omalizumab, and other anti-IgE therapies, in young children with multi-morbid asthma.
Patients with allergic multi-morbidities are more likely to be sensitized to a multitude of allergen molecules as a consequence of the so-called "molecular spreading" process. 74 These patients are easily identifiable by serum IgE testing with microarray technology, are less responsive to allergen immunotherapy, and would probably benefit from a more comprehensive anti-IgE treatment. 75 Specific trials of the impact of anti-IgE therapy in extremely polysensitized asthma patients are still lacking.
Although omalizumab is available for certain asthma patients aged 6-17 years, there is still room to improve accessibility to this drug. The omalizumab dosing table is an important consideration, whereby serum IgE levels and body weight must be taken into account when calculating drug dose. However, patients in whom pretreatment serum IgE levels exceed the upper limits of the dosing As omalizumab is a treatment that is administered every 2 or 4 weeks, the opportunity to administer the medication at home would be of great benefit for both patients and busy parents/guardians. Home administration is currently performed in France by a nurse or GP. However, the convenience of home use must be balanced with the risk of omalizumab-associated anaphylaxis, a serious, albeit very rare occurrence, affecting 0.1%-0.2% of patients receiving this biologic agent. 
| FINAL CONS IDER ATIONS
Asthma is a condition that often begins in young children. If asthma is adequately treated to establish control early in life, it is possible that these young patients will experience improved quality of life, improved lung function, reduced morbidity and asthma severity as adults, coupled with potential cost savings for healthcare systems. This hypothesis is supported by the recent Finnish experience, in which improved asthma control resulted in significant cost savings through reduced healthcare utilization. 79 In order to achieve this globally, the unmet needs in the management of asthma must be addressed.
As asthma is one of the most common conditions affecting children, 1 both primary care providers and specialists play important roles in diagnosis and management. 29 Furthermore, dissemination and implementation of evidence-based guidelines to ensure efficient and appropriate escalation of therapy are critical.
There is still a paucity of clinical evidence available, or being generated, to support specific treatment (including biologic) recommendations in all children, especially those <6 years of age, as well as a lack of non-steroid-based treatment options indicated for or as- Emerging therapies with novel targets and mechanisms of action also need to be studied in the pediatric patient population to ensure that therapy can be optimized for individual patients, regardless of age, disease severity, or endotype.
Since the approval of omalizumab over ten years ago, there have been many studies demonstrating its benefits in children ≥6 years of age; however, the biologic therapeutic options available to younger asthma patients are limited. With more evidence of efficacy and safety in this vulnerable patient population, there is considerable potential for early intervention with omalizumab in these very young patients to improve clinical outcomes and possibly reduce disease progression and/or severity. Studies that demonstrate efficacy of omalizumab in younger patients are needed and are planned.
Evidence of disease-modifying and/or disease prevention potential of omalizumab in pediatric asthma is needed to support the use of omalizumab in younger patients with uncontrolled disease who may significantly benefit from such therapy, but who are currently excluded. This unmet need may be addressed in part by the PARK study. Earlier intervention with omalizumab in appropriate patients may reduce or prevent the use of corticosteroids, inhaled or systemic, to maintain control in a patient population that is particularly vulnerable to adverse events associated with ICS or OCS.
Optimal management of pediatric asthma also involves the critical step of specialist referral of uncontrolled or difficult-to-treat patients in countries where asthma treatment is largely delivered by the GP/PCP. 14 An increased understanding of the potential benefits of anti-IgE therapy in multi-morbid asthmatic children is also needed to ensure that patients are optimally treated, with specific label changes implemented where appropriate.
Finally, it is widely acknowledged that there are many unmet needs which remain to be addressed in the management of pediatric asthma patients. Prevention measures, biomarker analyses, and age-specific treatment recommendations are just some of the ways in which the management of this condition may be driven forward in order to benefit as many patients and families as possible.
